HRP20211757T1 - Postupak kvantificiranja članova filogrupe i i filogrupe ii bakterije faecalibacterium prausnitzii i njihova upotreba kao bioloških biljega - Google Patents
Postupak kvantificiranja članova filogrupe i i filogrupe ii bakterije faecalibacterium prausnitzii i njihova upotreba kao bioloških biljega Download PDFInfo
- Publication number
- HRP20211757T1 HRP20211757T1 HRP20211757TT HRP20211757T HRP20211757T1 HR P20211757 T1 HRP20211757 T1 HR P20211757T1 HR P20211757T T HRP20211757T T HR P20211757TT HR P20211757 T HRP20211757 T HR P20211757T HR P20211757 T1 HRP20211757 T1 HR P20211757T1
- Authority
- HR
- Croatia
- Prior art keywords
- sample
- seq
- phgii
- subject
- phgi
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 22
- 241000605980 Faecalibacterium prausnitzii Species 0.000 title claims 19
- 238000011002 quantification Methods 0.000 title claims 2
- 239000000090 biomarker Substances 0.000 title 1
- 239000000523 sample Substances 0.000 claims 33
- 108091034117 Oligonucleotide Proteins 0.000 claims 18
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 15
- 208000028774 intestinal disease Diseases 0.000 claims 10
- 208000011231 Crohn disease Diseases 0.000 claims 8
- 239000003153 chemical reaction reagent Substances 0.000 claims 8
- 230000000968 intestinal effect Effects 0.000 claims 8
- 239000013074 reference sample Substances 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 241000588724 Escherichia coli Species 0.000 claims 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 238000003753 real-time PCR Methods 0.000 claims 5
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 4
- 244000005700 microbiome Species 0.000 claims 3
- 206010036774 Proctitis Diseases 0.000 claims 2
- 206010036783 Proctitis ulcerative Diseases 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 2
- 238000003748 differential diagnosis Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000009396 hybridization Methods 0.000 claims 2
- 108020004465 16S ribosomal RNA Proteins 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 208000014793 distal colitis Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000007901 in situ hybridization Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000002493 microarray Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 208000014965 pancolitis Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000012175 pyrosequencing Methods 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Claims (17)
1. In vitro postupak određivanja zastupljenosti članova filogrupe I bakterije Faecalibacterium prausnitzii (PHGI) i/ili članova filogrupe II bakterije Faecalibacterium prausnitzii (PHGII) kvantificiranjem gena za 16S rRNA specifičnog za filogrupu u crijevnom uzorku iz subjekta;
pri čemu se određivanje zastupljenosti PHGI sastoji u hibridizaciji sonde specifične za PHGI koja sadrži slijed SEQ ID NO: 3; i
pri čemu se određivanje zastupljenosti PHGII sastoji u hibridizaciji sonde specifične za PHGII koja sadrži slijed SEQ ID NO: 4.
2. Postupak detektiranja crijevne bolesti kod ljudskog subjekta, koji se sastoji u sljedećim koracima:
a. određivanja zastupljenosti članova filogrupe II bakterije Faecalibacterium prausnitzii (PHGII) u crijevnom uzorku iz navedenog subjekta postupkom u skladu s patentnim zahtjevom 1; i
b. uspoređivanja zastupljenosti PHGII, i/ili matematičke kombinacije sa zastupljenosti članova filogrupe I bakterije Faecalibacterium prausnitzii (PHGI) koju se određuje postupkom u skladu s patentnim zahtjevom 1, i/ili izborno matematičke kombinacije bilo koje od tih s ukupnom zastupljenosti F. prausnitzii (FT) i/ili zastupljenosti E. coli (EC), u uzorku iz subjekta s odgovarajućim vrijednostima u referentnom uzorku;
pri čemu značajno odstupanje u uzorku iz subjekta vrijednosti u odnosu na navedeni referentni uzorak ukazuje na crijevnu bolest;
pri čemu se navedenu crijevnu bolest bira iz skupine koju čine upalna crijevna bolest (IBD), sindrom iritabilnih crijeva (IBS) i kolorektalni rak (CRC); i pri čemu je navedeni referentni uzorak po mogućnosti uzorak iz zdravog subjekta i/ili uzorak iz pacijenta čija je crijevna bolest u povlačenju.
3. Postupak u skladu s patentnim zahtjevom 2, pri čemu je navedeni postupak postupak probiranja i/ili dijagnosticiranja crijevne bolesti kod ljudskog subjekta, a navedeni referentni uzorak je uzorak iz zdravog subjekta i/ili uzorak iz subjekta čija je crijevna bolest u povlačenju.
4. Postupak u skladu s patentnim zahtjevom 2, pri čemu je navedeni postupak postupak praćenja aktivnosti i/ili napredovanja crijevne bolesti kod ljudskog subjekta, a navedeni referentni uzorak je raniji uzorak iz istog subjekta.
5. Postupak u skladu s bilo kojim od patentnih zahtjeva 2 do 4, pri čemu je navedena crijevna bolest IBD, po mogućnosti ulcerozni kolitis (UC) ili Crohnova bolest (CD), poželjnije CD.
6. Postupak postavljanja diferencijalne dijagnoze fenotipova upalne crijevne bolesti (IBD) kod ljudskog subjekta, koji se sastoji u sljedećim koracima:
a. određivanja zastupljenosti članova filogrupe I bakterije Faecalibacterium prausnitzii (PHGI) i/ili članova filogrupe II bakterije Faecalibacterium prausnitzii (PHGII) u crijevnom uzorku iz navedenog subjekta postupkom u skladu s patentnim zahtjevom 1; i
b. uspoređivanja zastupljenosti PHGI i/ili PHGII, i/ili njihove matematičke kombinacije, i/ili izborno matematička kombinacija bilo koje od tih s ukupnom zastupljenosti F. prausnitzii (FT) i/ili zastupljenosti E. coli (EC), u uzorku iz subjekta s odgovarajućim vrijednostima u referentnom uzorku fenotipova IBD s kojima treba provesti usporedbu radi određivanja fenotipa IBD od kojeg boluje subjekt;
pri čemu uzorak iz subjekta koji pokazuje vrijednosti značajno slične onima iz navedenih fenotipova IBD ukazuje da subjekt boluje od navedenog fenotipa IBD; i
– pri čemu se navedene fenotipove IBD bira iz skupine koju čine: fenotipovi CD koje određuje jedan ili više, po mogućnosti svi, od sljedećih parametara:
◦ lokacija bolesti;
◦ dob prilikom dijagnosticiranja; i
◦ ponašanje;
– fenotipovi UC koje određuje jedan ili više, po mogućnosti svi, od sljedećih parametara:
◦ lokacija ili opseg bolesti; i
◦ težina.
7. Postupak u skladu s patentnim zahtjevom 6, pri čemu se navedene fenotipove IBD bira iz skupine koju čine:
– fenotipovi CD koje čine ilealni CD (I-CD), ileokolonski CD (IC-CD) i kolonski CD (C-CD); i
– fenotipovi UC koje čine ulcerozni proktitis (UC-E1), distalni kolitis (UC-E2) i opsežni UC ili pankolitis (UC-E3).
8. Postupak dijagnosticiranja C-CD kod ljudskog subjekta koji boluje od IBD kod kojeg je zahvaćeno debelo crijevo, koji se sastoji u sljedećim koracima:
i. određivanja zastupljenosti ciljnog mikroorganizma u crijevnom uzorku iz navedenog subjekta, pri čemu se navedeni ciljni mikroorganizam bira iz skupine koju čine članovi filogrupe I bakterije Faecalibacterium prausnitzii (PHGI) i članovi filogrupe II bakterije Faecalibacterium prausnitzii (PHGII); i
ii. uspoređivanja razina zastupljenosti u uzorku iz subjekta s razinama u referentnom uzorku, pri čemu značajno smanjenje razina zastupljenosti u uzorku iz subjekta u odnosu na navedeni referentni uzorak ukazuje na C-CD;
pri čemu je po mogućnosti navedeni ciljni mikroorganizam PHGII.
9. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 8, pri čemu se određivanje zastupljenosti PHGI i/ili PHGII, te izborno određivanje zastupljenosti FT i/ili EC, provodi molekulskim postupkom kojeg se bira iz skupine koju čine kvantitativna lančana reakcija polimerazom (qPCR), PCR-pirosekvenciranje, fluorescentna hibridizacija in situ (FISH), mikrorešetke, te PCR-ELISA, gdje se po mogućnosti kvantificiranje provodi qPCR-om.
10. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 9, pri čemu se određivanje zastupljenosti PHGI provodi sondom koju čini oligonukleotidni slijed SEQ ID NO: 3; i/ili
pri čemu se određivanje zastupljenosti PHGII provodi sondom koju čini oligonukleotidni slijed SEQ ID NO: 4.
11. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 10, pri čemu se određivanje zastupljenosti PHGI provodi qPCR-om, uz početnice koje čine oligonukleotidni sljedovi SEQ ID NO: 1 i SEQ ID NO: 2, ili slijed koji im je istovjetan najmanje 75 %; i sondu koju čini oligonukleotidni slijed SEQ ID NO: 3; i/ili
pri čemu se određivanje zastupljenosti PHGII provodi qPCR-om, uz početnice koje čine oligonukleotidni sljedovi SEQ ID NO: 1 i SEQ ID NO: 2, ili slijed koji im je istovjetan najmanje 75 %; i sondu koju čini oligonukleotidni slijed SEQ ID NO: 4.
12. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 11, pri čemu se DNA dobiva iz crijevnog uzorka prije određivanja zastupljenosti PHGI i/ili PHGII, te izborno FT i/ili EC.
13. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 12, pri čemu se navedeni crijevni uzorak bira iz skupine koju čine biopsija sluznice i uzorak stolice, a po mogućnosti je uzorak stolice.
14. Komplet koji sadrži:
a. reagens za određivanje zastupljenosti članova filogrupe I bakterije Faecalibacterium prausnitzii (PHGI) koju čine:
– par nukleinskokiselinskih početnica kojeg čine oligonukleotidni sljedovi SEQ ID NO: 1 i SEQ ID NO: 2 ili oligonukleotidni sljedovi koji su im istovjetni najmanje 75 %; i
– sonda koju čini oligonukleotidni slijed SEQ ID NO: 3; i/ili
b. reagens za određivanje zastupljenosti članova filogrupe II bakterije Faecalibacterium prausnitzii (PHGII) koju čine:
– par nukleinskokiselinskih početnica kojeg čine oligonukleotidni sljedovi SEQ ID NO: 1 i SEQ ID NO: 2 ili oligonukleotidni sljedovi koji su im istovjetni najmanje 75 %; i
– sonda koju čini oligonukleotidni slijed SEQ ID NO: 4;
c. izborno, upute o upotrebi jednog ili više navedenih reagensa u određivanju zastupljenosti PHGI, i/ili PHGII, iz uzorka iz ljudskih crijeva.
15. Upotreba kompleta za detektiranje crijevne bolesti i/ili za postavljanje diferencijalne dijagnoze fenotipova IBD; pri čemu navedeni komplet sadrži:
a. reagens za određivanje zastupljenosti članova filogrupe I bakterije Faecalibacterium prausnitzii (PHGI) koju čine sonda koja sadrži slijed SEQ ID NO: 3; i/ili
b. reagens za određivanje zastupljenosti članova filogrupe II bakterije Faecalibacterium prausnitzii (PHGII) koju čine sonda koja sadrži slijed SEQ ID NO: 4; i
c. izborno, upute o upotrebi jednog ili više navedenih reagensa u određivanju zastupljenosti PHGI, i/ili PHGII, iz uzorka iz ljudskih crijeva;
pri čemu se navedenu crijevnu bolest bira iz skupine koju čine upalna crijevna bolest (IBD), sindrom iritabilnih crijeva (IBS) i kolorektalni rak (CRC).
16. Upotreba kompleta u skladu s patentnim zahtjevom 15, pri čemu:
a. navedeni reagens za određivanje zastupljenost PHGI se sastoji od:
– para nukleinskokiselinskih početnica kojeg čine oligonukleotidni sljedovi SEQ ID NO: 1 i SEQ ID NO: 2 ili oligonukleotidni sljedovi koji su im istovjetni najmanje 75 %; i
– sonda koju čini oligonukleotidni slijed SEQ ID NO: 3; i/ili
b. navedeni reagens za određivanje zastupljenost PHGII se sastoji od:
– para nukleinskokiselinskih početnica kojeg čine oligonukleotidni sljedovi SEQ ID NO: 1 i SEQ ID NO: 2 ili oligonukleotidni sljedovi koji su im istovjetni najmanje 75 %; i
– sonda koju čini oligonukleotidni slijed SEQ ID NO: 4.
17. Molekula nukleinske kiseline koju se bira iz skupine koju čine SEQ ID NO: 3 i SEQ ID NO: 4.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382427.1A EP3130680A1 (en) | 2015-08-11 | 2015-08-11 | Method for the detection, follow up and/or classification of intestinal diseases |
| EP16754468.3A EP3334838B1 (en) | 2015-08-11 | 2016-08-11 | Method for the quantification of faecalibacterium prausnitzii phylogroup i and/or phylogroup ii members and the use thereof as biomarkers |
| PCT/EP2016/069188 WO2017025617A1 (en) | 2015-08-11 | 2016-08-11 | Method for the quantification of faecalibacterium prausnitzii phylogroup i and/or phylogroup ii members and the use thereof as biomarkers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211757T1 true HRP20211757T1 (hr) | 2022-02-18 |
Family
ID=53938288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211757TT HRP20211757T1 (hr) | 2015-08-11 | 2016-08-11 | Postupak kvantificiranja članova filogrupe i i filogrupe ii bakterije faecalibacterium prausnitzii i njihova upotreba kao bioloških biljega |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11299788B2 (hr) |
| EP (2) | EP3130680A1 (hr) |
| JP (2) | JP7095210B2 (hr) |
| KR (1) | KR20180048696A (hr) |
| CN (2) | CN108474037A (hr) |
| AU (1) | AU2016306627B2 (hr) |
| CA (1) | CA2995308A1 (hr) |
| DK (1) | DK3334838T3 (hr) |
| ES (1) | ES2901465T3 (hr) |
| HK (1) | HK1257108A1 (hr) |
| HR (1) | HRP20211757T1 (hr) |
| IL (1) | IL257461B (hr) |
| MX (1) | MX2018001697A (hr) |
| PT (1) | PT3334838T (hr) |
| SI (1) | SI3334838T1 (hr) |
| WO (1) | WO2017025617A1 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230149497A1 (en) | 2017-06-02 | 2023-05-18 | Goodgut S.L. | Grape skin for use in the treatment of dysbiosis |
| CA3084012A1 (en) * | 2017-11-02 | 2019-05-09 | Mitsubishi Chemical Corporation | Intraoral examination method using information on bacterial group related to clinical indexes |
| US11649508B2 (en) | 2017-12-15 | 2023-05-16 | Vib Vzw | Inflammation associated, low cell count enterotype |
| CZ2018456A3 (cs) * | 2018-09-08 | 2020-01-02 | Výzkumný ústav veterinárního lékařství, v. v. i. | Způsob detekce Faecalibacterium prausnitzii pomocí metody PCR v reálném čase a sada primerů pro tento způsob detekce F. prausnitzii |
| CA3118304A1 (en) * | 2018-11-02 | 2020-05-07 | The Regents Of The University Of California | Methods to diagnose and treat cancer using non-human nucleic acids |
| JP2022523596A (ja) | 2019-03-13 | 2022-04-25 | グッドガット エッセ．エッレ． | 結腸直腸進行新生物、進行腺腫、及び／又は結腸直腸癌をスクリーニング、診断、及び／又はモニタリングする改善された方法 |
| WO2023049838A1 (en) * | 2021-09-23 | 2023-03-30 | Flagship Pioneering Innovations Vi, Llc | Diagnosis and treatment of diseases and conditions of the intestinal tract |
| CN114015761A (zh) * | 2021-09-24 | 2022-02-08 | 上海交通大学医学院附属瑞金医院 | 粪便tyrDC基因丰度作为预测左旋多巴疗效生物标志物的应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6174681B1 (en) | 1999-03-05 | 2001-01-16 | Mayo Foundation For Medical Education And Research | Method and probe set for detecting cancer |
| FR2820145B1 (fr) * | 2001-01-31 | 2004-01-23 | Aventis Pharma Sa | Souche de levure produisant des steroides de facon autonome |
| AU2003245465A1 (en) | 2002-02-13 | 2003-09-04 | Medimolecular Pty. Ltd. | Method of isolating nucleic acids from stool samples |
| US7696334B1 (en) * | 2002-12-05 | 2010-04-13 | Rosetta Genomics, Ltd. | Bioinformatically detectable human herpesvirus 5 regulatory gene |
| EP1752536A4 (en) | 2004-05-11 | 2008-04-16 | Alphagen Co Ltd | POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME |
| US7323308B2 (en) * | 2004-09-03 | 2008-01-29 | Affymetrix, Inc. | Methods of genetic analysis of E. coli |
| US7901882B2 (en) * | 2006-03-31 | 2011-03-08 | Affymetrix, Inc. | Analysis of methylation using nucleic acid arrays |
| WO2008021290A2 (en) * | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
| WO2011009099A1 (en) | 2009-07-16 | 2011-01-20 | The Regents Of The University Of California | Metabolic biomarkers of crohn's disease |
| CA2776420A1 (en) * | 2009-10-05 | 2011-04-14 | Aak Patent B.V. | Methods for diagnosing irritable bowel syndrome |
| US8906610B2 (en) | 2010-02-08 | 2014-12-09 | The Regents Of The University Of California | Using phylogenetic probes for quantification of stable isotope labeling and microbial community analysis |
| WO2012170478A2 (en) | 2011-06-06 | 2012-12-13 | The University Of North Carolina At Chapel Hill | Methods and kits for detecting adenomas, colorectal cancer, and uses thereof |
| BR112015009138A2 (pt) * | 2012-10-23 | 2020-10-20 | Caris Life Sciences Switzerland Holdings, S.A.R.L. | métodos para caracterizar um câncer |
| RU2015137415A (ru) * | 2013-03-05 | 2017-04-10 | Рейксуниверситет Гронинген | Применение штамма htf-f фекальной бактерии prausnitzii htf-f (dsm 26943) для подавления воспаления |
| WO2014138999A1 (en) * | 2013-03-14 | 2014-09-18 | University Of Ottawa | Methods for the diagnosis and treatment of inflammatory bowel disease |
| WO2014197607A1 (en) * | 2013-06-05 | 2014-12-11 | The Regents Of The University Of California | Detection of tick-borne diseases |
| EP2876167A1 (en) | 2013-11-21 | 2015-05-27 | Institut Gustave Roussy | Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment |
| ES2661684T3 (es) | 2014-03-03 | 2018-04-03 | Fundacio Institut D'investigació Biomèdica De Girona Dr. Josep Trueta | Método para diagnosticar cáncer colorrectal a partir de una muestra de heces humanas mediante PCR cuantitativa |
| CN104745620A (zh) * | 2015-03-03 | 2015-07-01 | 昆明理工大学 | 蚕豆vfpp1c基因的植物表达载体及其应用 |
-
2015
- 2015-08-11 EP EP15382427.1A patent/EP3130680A1/en not_active Withdrawn
-
2016
- 2016-08-11 PT PT167544683T patent/PT3334838T/pt unknown
- 2016-08-11 CN CN201680059564.XA patent/CN108474037A/zh active Pending
- 2016-08-11 US US15/751,805 patent/US11299788B2/en active Active
- 2016-08-11 EP EP16754468.3A patent/EP3334838B1/en active Active
- 2016-08-11 DK DK16754468.3T patent/DK3334838T3/da active
- 2016-08-11 MX MX2018001697A patent/MX2018001697A/es unknown
- 2016-08-11 HR HRP20211757TT patent/HRP20211757T1/hr unknown
- 2016-08-11 AU AU2016306627A patent/AU2016306627B2/en active Active
- 2016-08-11 CA CA2995308A patent/CA2995308A1/en active Pending
- 2016-08-11 JP JP2018527012A patent/JP7095210B2/ja active Active
- 2016-08-11 ES ES16754468T patent/ES2901465T3/es active Active
- 2016-08-11 SI SI201631380T patent/SI3334838T1/sl unknown
- 2016-08-11 CN CN202211643379.9A patent/CN115976239A/zh active Pending
- 2016-08-11 WO PCT/EP2016/069188 patent/WO2017025617A1/en active Application Filing
- 2016-08-11 KR KR1020187006886A patent/KR20180048696A/ko not_active Application Discontinuation
-
2018
- 2018-02-11 IL IL257461A patent/IL257461B/en unknown
- 2018-12-20 HK HK18116361.7A patent/HK1257108A1/zh unknown
-
2021
- 2021-10-22 JP JP2021173197A patent/JP2022031644A/ja active Pending
-
2022
- 2022-03-01 US US17/683,926 patent/US20220307075A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017025617A1 (en) | 2017-02-16 |
| AU2016306627B2 (en) | 2022-01-13 |
| PT3334838T (pt) | 2021-11-23 |
| SI3334838T1 (sl) | 2022-01-31 |
| DK3334838T3 (da) | 2021-11-15 |
| JP7095210B2 (ja) | 2022-07-05 |
| CA2995308A1 (en) | 2017-02-16 |
| CN108474037A (zh) | 2018-08-31 |
| HK1257108A1 (zh) | 2019-10-11 |
| JP2018525035A (ja) | 2018-09-06 |
| EP3130680A1 (en) | 2017-02-15 |
| US20190024146A1 (en) | 2019-01-24 |
| AU2016306627A1 (en) | 2018-03-15 |
| US11299788B2 (en) | 2022-04-12 |
| ES2901465T3 (es) | 2022-03-22 |
| WO2017025617A8 (en) | 2017-07-27 |
| MX2018001697A (es) | 2019-04-29 |
| JP2022031644A (ja) | 2022-02-22 |
| EP3334838A1 (en) | 2018-06-20 |
| EP3334838B1 (en) | 2021-10-06 |
| IL257461A (en) | 2018-04-30 |
| CN115976239A (zh) | 2023-04-18 |
| IL257461B (en) | 2022-05-01 |
| US20220307075A1 (en) | 2022-09-29 |
| KR20180048696A (ko) | 2018-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211757T1 (hr) | Postupak kvantificiranja članova filogrupe i i filogrupe ii bakterije faecalibacterium prausnitzii i njihova upotreba kao bioloških biljega | |
| CN113227468A (zh) | 感染性疾病的检测和预测 | |
| JP2020146052A (ja) | 定量的ｐｃｒによってヒトの糞便試料から大腸癌を診断する方法、プライマー及びキット | |
| JP2021090451A (ja) | 大腸癌の診断方法 | |
| WO2016060278A1 (ja) | 大腸癌に対する薬物療法の感受性を予測する方法 | |
| CA2959670C (en) | Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm | |
| NZ569788A (en) | RNA transcript of BGN as a gene expression markers for colorectal cancer prognosis | |
| CA2829503A1 (en) | Method for identifying a subset of polynucleotides from an initial set of polynucleotides corresponding to the human genome for the in vitro determination of the severity of the host response of a patient | |
| US20220073996A1 (en) | Model for predicting treatment responsiveness based on intestinal microbial information | |
| Gimondi et al. | Circulating miRNA panel for prediction of acute graft-versus-host disease in lymphoma patients undergoing matched unrelated hematopoietic stem cell transplantation | |
| Vinayanuwattikun et al. | Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer | |
| Fang et al. | Circulating miR-205: a promising biomarker for the detection and prognosis evaluation of bladder cancer | |
| US20210301350A1 (en) | Lung cancer determinations using mirna | |
| EP3083988A2 (en) | Different levels in blood cell samples of emt-markers for the diagnosis of cancer, in particular of colorectal (crc) and pancreatic (pc) cancer | |
| WO2014187884A2 (en) | Mirnas as non-invasive biomarkers for heart failure | |
| CA2699433A1 (en) | Use of polynucleotides for detecting gene activities for distinguishing between local and systemic infection | |
| CA2989480C (en) | Kit and method for the diagnosis/prognosis of idiopathic scoliosis | |
| Chen et al. | Identification of a four-microRNA panel in serum for screening renal cell carcinoma | |
| TWI571514B (zh) | 評估罹患大腸直腸癌風險的方法 | |
| EP3724358A1 (en) | A new inflammation associated, low cell count enterotype | |
| WO2015121737A4 (en) | Transcriptomic biomarkers, method for determination thereof and use of trnascriptomic biomarkers for individual risk assessment of developing post-infraction heart failure | |
| RU2680268C1 (ru) | Система детекции наиболее значимых прокариотических представителей микробиоты кишечника человека на основе пцр панели | |
| EP3212803A1 (en) | Mirnas as non-invasive biomarkers for inflammatory bowel disease | |
| TWI626314B (zh) | 評估罹患大腸直腸癌風險的方法 | |
| JP2021500921A (ja) | Ｆｉｍｈ遮断剤の治療効率を評価するための新規ツール |